Uncategorized
Regeneron reports 21% rise in total revenues for second quarter
Total revenues for Regeneron increased by 21% to $1.213 billion in the second quarter, up from $999 million in the second quarter of 2015, according to a press release.U.S. net sales of Eylea (aflibercept) increased 27% to $831 million, up from $655 million in the second quarter of 2015, while global net sales of Eylea increased 33% to $1.32 billion compared with the same period a year earlier.